Calyxt initiated with a Neutral at Goldman Sachs. Goldman Sachs analyst Adam Samuelson started Calyxt with a Neutral rating and $18 price target. The analyst views the company as a food gene-editor of the future, but prefers to wait on the sidelines with respect to the shares pending evidence that it can effectively scale.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.